Faron Pharmaceuticals Oy’s (LON:FARN) Clevegen cancer treatment has shown its safety credentials in its initial clinical trials.

The biopharma firm said that feedback from a dose escalation study had confirmed that Clevegen had “good tolerability” across all dosing levels tested with no dose limiting toxicity observed, adding that lower doses could potentially induce a “stronger immune response” and was now considering tests on lower dose levels of around 0.1-1 milligrams per kilo (mg/kg) rather than higher dosages of 20 mg/kg as previously planned.

WATCH: ‘Immune activation from Clevegen has now been demonstrated’ Faron Pharma CEO

Faron also said in line with advice from the study’s data monitoring committee it would expand its patient cohort for part I of the trial to 30 to determine optimal dosage before moving to part II.

“Good safety was the first priority of Part I and now we have obtained that status”, said Faron’s chief executive Markku Jalkanen.

He added that if the optimal dose for Clevegen was at the lower end of the scale it would provide an “unusually high safety margin” for the treatment either alone or in combination with other cancer therapies.